JudySWangMD

Oncology • Sarasota, FL

Phase I Clinical Trialist, FCS/SCRI

Join to view full profile

Dr. Wang is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wang's full profile

Already have an account?

Office
600 N Cattlemen Rd
Ste 200
Sarasota, FL 34232
Phone+1 941-377-9993

Fax+1 941-343-0026

Summary

Early phase, including first-in-human, medical oncologist and clinical trial investigator in all advanced solid tumors

Florida Cancer Specialists and Research Institute

Florida Cancer Specialists is proud to offer cancer treatment tailored to each individual, including a robust clinical trial program including Phase I.

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2012 - 2015
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Internal Medicine, 2009 - 2012
Pennsylvania State University College of MedicineClass of 2009
Johns Hopkins UniversityBS, Biomedical Engineering, 1999 - 2003

Certifications & Licensure

FL State Medical License 2015 - 2025
MD State Medical License 2012 - 2015
PA State Medical License 2009 - 2012
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer Start of enrollment: 2014 Aug 01
Completed
Phase 1
Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck Start of enrollment: 2015 Aug 06
Active, not recruiting
Phase 1, Phase 2
AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors Start of enrollment: 2015 Aug 06
Completed
Phase 1
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors Start of enrollment: 2015 Nov 01
Completed
Phase 1, Phase 2
A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) Start of enrollment: 2015 Nov 09
Terminated
Phase 1, Phase 2
Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer Start of enrollment: 2016 Mar 01
Completed
Phase 1
A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors. Start of enrollment: 2015 Oct 28
Completed
Phase 1
Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours Start of enrollment: 2015 Dec 28
Active, not recruiting
Phase 1
A Phase 1 Trial of a Novel XPO1 Inhibitor in Patients With Advanced Solid Tumors Start of enrollment: 2016 Feb 23
Completed
Phase 1
Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies Start of enrollment: 2016 Jan 01
Recruiting
Phase 1
A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors Start of enrollment: 2016 Jun 16
Completed
Phase 1
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) Start of enrollment: 2016 Jul 08
Recruiting
Phase 1
Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors Start of enrollment: 2016 Sep 01
Completed
Phase 1
Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer Start of enrollment: 2016 Dec 01
Completed
Phase 1, Phase 2
A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer Start of enrollment: 2017 Jan 06
Completed
Phase 1
Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours Start of enrollment: 2017 May 15
Completed
Phase 1
Study of AGEN2034 in Advanced Tumors and Cervical Cancer Start of enrollment: 2017 Apr 11
Completed
Phase 1, Phase 2
AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas Start of enrollment: 2017 Jun 30
Completed
Phase 1
Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer Start of enrollment: 2017 Aug 17
Completed
Phase 1, Phase 2
A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors Start of enrollment: 2017 Oct 25
Completed
Phase 2
Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients Start of enrollment: 2017 Nov 14
Completed
Phase 1
Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) Start of enrollment: 2018 Apr 10
Completed
Phase 2
A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors Start of enrollment: 2018 Apr 23
Recruiting
Phase 1
Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer Start of enrollment: 2019 Jun 06
Completed
Phase 2
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer Start of enrollment: 2019 Nov 14
Active, not recruiting
Phase 1, Phase 2
Roles: Contact
A Study of EP0031 in Patients With Advanced RET-altered Malignancies Start of enrollment: 2022 Sep 30
Recruiting
Phase 1, Phase 2
Roles: Contact
First in Human Study of IMGN151 in Recurrent Endometrial Cancer and Recurrent, High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Start of enrollment: 2023 Jan 11
Recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

104 citations
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research HIV Working Group.
Thomas S. Uldrick, Gwynn Ison, Michelle A. Rudek, Ariela Noy, Karl Schwartz
Journal of Clinical Oncology. 2017-10-02
56 citations
Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-Type TP53.
Mansoor N. Saleh, Manish R. Patel, Todd M. Bauer, Sanjay Goel, Gerald Steven Falchook
Clinical Cancer Research. 2021-10-01
44 citations
Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity
Devalingam Mahalingam, Judy S. Wang, Erika Hamilton, John Sarantopoulos, John Nemunaitis
Clinical Cancer Research. 2019-06-15

Lectures

A Phase I Trial of a Guadecitabine (SGI-110) and Irinotecan in Metastatic Colorectal Cancer Patients Previously Exposed to Irinotecan
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Florida Cancer Specialists & Research Institute Contributing to Transformative Cancer Therapies WorldwideSeptember 12th, 2024
Florida Cancer Specialists & Research Institute Contributing to Rapid Advancements in Breast Cancer TreatmentDecember 13th, 2022
Sarah Cannon to Present Latest Cancer Research Insights at 2021 ASCO® Annual MeetingJune 4th, 2021
Join now to see all